HUBBARD, Ohio, April 24, 2012 /PRNewswire/ -- A
well-respected, independent, third-party laboratory has tested for
Tuberculosis (TB) using NanoLogix BNP (BioNanoPore) test kits and
achieved the detection of live TB colonies in 4 to 5 days.
Standard culture times for conventional technologies take a minimum
of 16 to 21 days to achieve similar results. In concurrent
tests for TB at the same facility, using Nanologix BNF
(BioNanoFilter) test kits, Antibody/Antigen TB-specific test
results were obtained in 1 hour 30 minutes. For research and
publication purposes, all test results were confirmed with
PCR. Comprehensive results of these independent tests are
currently undergoing editing for publication in a major
peer-reviewed, scientific journal.
Group B Strep Research Published
Results of an ongoing (status: 340 of 350 patients complete)
Group B streptococcus clinical study being conducted at the
University of Texas Health Science Center -
Houston, using NanoLogix technology, has been published in
the April 2012 edition of the Journal
of Diagnostic Microbiology and Infectious Disease. The paper is
titled, Optimization of a rapid diagnostic test for detection of
group B streptococcus from antepartum patients. Authored
by Dr. Jonathan Faro, et al, a full
abstract of the paper can be found at
http://www.sciencedirect.com/science/article/pii/S0732889312001071
NanoLogix "Flat Pack" Packaging Method Achieves Milestone
With One Year Shelf Life
A major independent research facility is evaluating the shelf
life of petri-based technology sealed in NanoLogix patent-pending
"Flat-Pack" vacuum packaging. The results to date demonstrate
shelf life of at least one year. The recommended shelf life
for standard non-NanoLogix petri-based products packaged in
standard packaging is currently three months. To read the
scientific assessment, please visit
http://www.nanologix.com/resources.html
New Science Advisory Board Member
NanoLogix welcomes Mark Wheeler,
MD to its Science Advisory Board. Dr. Wheeler brings an
extensive medical, investment and business background to the
Advisory Board. For more information about Dr. Wheeler please
visit http://nanologix.com/about/team.html.
First and Second Quarter Business Developments
At the 2012 ASM BioDefense and Emerging Diseases Conference and
the Food Safety Summit, NanoLogix received strong interest in its
technology from multiple corporate and institutional entities,
domestic and foreign. NanoLogix exhibited at both events, which
were held in February and April, respectively, in Washington D.C.
In addition to US sales, the company has recently shipped BNP
and/or BNF test kits to Europe,
India, Turkey and the Middle East.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing.
Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and
antibiotic sensitivity
For more information visit www.nanologix.com.
Media Contact:
Lisa Ann Pinkerton
408-806-9626
Lisaann@technicacommunications.com
Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
SOURCE NanoLogix, Inc.